Status:
COMPLETED
Dose-response of Albuterol in Asthmatics
Lead Sponsor:
Nemours Children's Clinic
Conditions:
Asthma
Eligibility:
All Genders
8-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study was to determine the lung function response after increasing doses of albuterol (a bronchodilator) in children and adults with asthma.
Detailed Description
Inhaled short-acting b2-agonists (SABA) are the most potent bronchodilators used today to treat acute symptoms of asthma and albuterol, a partial b2-agonist, is the most frequently prescribed asthma m...
Eligibility Criteria
Inclusion
- Eligibility Criteria:
- Well-defined history of physician diagnosed asthma
- Any ethnic background
- 8 to 65 years old
- Baseline pre-bronchodilator FEV1 of 40% to 80% predicted for age, height, and gender
- No oral corticosteroid use, emergency room visits, or hospitalizations within the previous 3 months
- Nonsmokers or less than a 5 pack-year history with no smoking in the previous year
- Normal physical exam and no confounding diseases were selected
- Able to withhold inhaled short-acting b2-agonists or inhaled anticholinergic drugs for 8 hours, oral antihistamines for 5 days, theophylline for 24 hours, and cromolyn, nedocromil, and inhaled corticosteroids for 2 hours prior to the study.
Exclusion
Key Trial Info
Start Date :
July 1 1993
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 1994
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00940927
Start Date
July 1 1993
End Date
October 1 1994
Last Update
May 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nemours Children's Clinic
Jacksonville, Florida, United States, 32207